Tanabe Pharma Corporation: Insulin Resistance trials

The registry lists 11 Insulin Resistance studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 2 2Phase 3 5Phase 4 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02622113Phase 4Results posted
• Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedNCT02227849Phase 4Results posted
• Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02220920Phase 4Results posted
• Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT02081599Phase 4Results posted
• Long-term Safety Study of MP-513 in Patients With Type 2 DiabetesCompletedNCT01301833Phase 3Results posted
• Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes MellitusCompletedNCT01072331Phase 3Results posted
• Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 DiabetesCompletedNCT01026194Phase 3Results posted
• Monotherapy Study of MP-513 in Patients With Type 2 DiabetesCompletedNCT00998881Phase 3Results posted
• Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 DiabetesCompletedNCT00974090Phase 3Results posted
• Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00971243Phase 2Results posted
• Efficacy and Safety Study of MP-513 in Patients With Type 2 DiabetesCompletedNCT00628212Phase 2Results posted